

(6) Adequacy of the proposal to evaluate the outcomes of the activities proposed; and

(7) The cost effectiveness of the application.

#### Federal Responsibilities Under Cooperative Agreements

Federal responsibilities under the cooperative agreement, in addition to the usual monitoring and technical assistance, will include: (1) Participation in the development and approval of an initial workplan, in accord with changing events in government policies and in the health care environment, and modification thereof, as appropriate; (2) consultation and cooperation with the grantee regarding the grantee's preparation and dissemination of materials; and (3) approval of specific studies and projects.

#### Other Award Information

These awards are not subject to the provision of Executive Order 12372 or the Public Health System Reporting Requirement.

Dated: November 1, 1996.

Ciro V. Sumaya,  
Administrator.

[FR Doc. 96-28638 Filed 11-6-96; 8:45 am]

BILLING CODE 4160-15-P

#### Advisory Council; Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), announcement is made of the following National Advisory bodies scheduled to meet during the month of December 1996.

*Name:* Advisory Commission on Childhood Vaccines (ACCV)

*Date and Time:* December 4, 1996; 10:00 a.m.-5:00 p.m. December 5, 1996; 9:00 a.m.-5:00 p.m.

*Place:* Parklawn Building, Conference Rooms G & H, 5600 Fishers Lane, Rockville, Maryland 20857.

The meeting is open to the public.

The first day of the meeting, Tuesday, December 4, will consist of a meeting of one of the Commission's workgroups.

*Name:* Workgroup on Intent, Provisions and Process

*Agenda:* Agenda items will include, but not be limited to, discussion of the following issues: Program and policy issues related to the operation of the Vaccine Injury Compensation Program.

The full Commission will meet on Thursday, December 5, from 9:00 a.m. to 5:00 p.m. Agenda items will include, but not be limited to: A report from the Workgroup on Intent, Provision, and Process; a review of the proposed

changes to the Vaccine Information Statements for polio and DTP (DTaP); and routine Program reports.

Public comment will be permitted before the end of the Workgroup meeting on December 4, as well as the full Commission meeting on December 5. Oral presentations will be limited to 5 minutes per public speaker.

Persons interested in providing an oral presentation should submit a written request, along with a copy of their presentation to: Ms. Melissa Palmer, Principal Staff Liaison, Division of Vaccine Injury Compensation, Bureau of Health Professions, Health Resources and Services Administration, Room 8A-35, 5600 Fishers Lane, Rockville, MD 20857, Telephone (301) 443-6593. Requests should contain the name, address, telephone number, and any business or professional affiliation of the person desiring to make an oral presentation. Groups having similar interests are requested to combine their comments and present them through a single representative. The allocation of time may be adjusted to accommodate the level of expressed interest. The Division of Vaccine Injury Compensation Program will notify each presenter by mail or telephone of their assigned presentation time. Persons who do not file an advance request for presentation, but desire to make an oral statement, may sign-up in Conference Rooms G & H on December 4-5. These persons will be allocated time as time permits.

Anyone requiring information regarding the Commission should contact Ms. Palmer.

Agenda Items are subject to change as priorities dictate.

Dated: November 4, 1996.

Jackie E. Baum,

Advisory Committee Management Officer,  
HRSA.

[FR Doc. 96-28680 Filed 11-6-96; 8:45 am]

BILLING CODE 4160-15-P

#### National Institutes of Health

##### National Cancer Institute; Notice of Meeting of the National Cancer Advisory Board and Its Subcommittees

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the National Cancer Advisory Board, National Cancer Institute, and its Subcommittees on November 18-20, 1996. Except as noted below, the meetings of the Board and its Subcommittees will be open to the public to discuss issues relating to committee business as indicated in the

notice. Attendance by the public will be limited to space available.

The Committee Management Office, National Cancer Institute, National Institutes of Health, Executive Plaza North, Room 630E, 9000 Rockville Pike, Bethesda, Maryland 20892 (301/496-5708), will provide summaries of the meetings and rosters of the Board members, upon request.

A portion of the Board meeting will be closed to the public in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and sec. 10(d) of Public Law 92-463, for the review, discussion and evaluation and discussion of issues pertaining to intramural programmatic areas and/or NCI personnel and discussion of recommendations regarding NCI staff. These discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning the individuals associated with the programs, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Carole Frank, Committee Management Specialist, at 301/496-5708 in advance of the meeting.

*Name of Committee:* Policy and Advocacy Ad Hoc Subcommittee.

*Contact Person:* Dr. Marvin R. Kalt, Executive Secretary, National Cancer Institute, NIH, Executive Plaza North, Room 600A, 61030 Executive Blvd., Bethesda, MD 20892-7405; (301) 496-4291.

*Date of Meeting:* Nov. 18, 1996.

*Place of Meeting:* Conference Room 8, Building 31C, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892.

*Open:* 7:00 pm to 8:00 pm.

*Agenda:* To discuss the role of the NCAB in advocacy activities and in advising NCI on extramural and intramural policy.

*Name of Committee:* Subcommittee on Clinical Investigations.

*Contact Person:* Dr. Robert E. Wittes, Acting Executive Secretary, National Cancer Institute, NIH, Building 31, Room 3A52, 9000 Rockville Pike, Bethesda, MD 20892; (301) 496-4291.

*Date of Meeting:* November 18, 1996.

*Place of Meeting:* Conference Room 8, Building 31C, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892.

*Open:* 8:15 pm to 9:30 pm.

*Agenda:* To discuss clinical trials reimbursement issues.

*Name of Committee:* National Cancer Advisory Board.

*Contact Person:* Dr. Marvin R. Kalt, Executive Secretary, National Cancer Institute, NIH, Executive Plaza North, Room 600A, 6130 Executive Blvd., Bethesda, MD 20892-7405; (301) 496-5147.

*Dates of Meeting:* November 19–20, 1996.

*Place of Meeting:* Conference Room 10, Building 31C, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892.

*Open:* November 19—8:30 am to approximately 4 pm; November 20—8:30 am to approximately 1 pm.

*Agenda:* The NCI Director's Report; Legislative Update; Report of the President's Cancer Panel; Outcome of the NCAB Retreat and Chances in Subcommittee Structure; NCI Planning Principles and NCI Planning Retreat Outcomes; FY 99 Bypass Planning Procedures; New Business; Intercultural Cancer Council C-Chair Remarks; Program Review Group Reports; Report by the Office of Advisory Activities; Bishop-Calabresi Report Update; Cancer Genome Anatomy Project; Board of Scientific Counselors and Board of Scientific Advisors Activities and their interface with this Board; Subcommittee/Ad Hoc Subcommittee reports; and Integration of Biotechnology Development into NCI Programs.

*Closed:* November 19—4:00 pm to approximately 5 pm.

*Agenda:* For review and discussion of intramural programs and personnel.

This notice is being published less than 15 days prior to the meeting due to the urgent need to proceed with the meeting as scheduled in order to address these issues in a timely manner.

Catalog of Federal Domestic Assistance Program Numbers: (93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: October 30, 1996.

Paula N. Hayes,

*Acting Committee Management Officer, NIH.*

[FR Doc. 96–28632 Filed 11–6–96; 8:45 am]

**BILLING CODE 4140–01–M**

### **National Heart, Lung, and Blood Institute; Notice of a Closed Meeting**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Heart, Lung, and Blood Institute Special Emphasis Panel (SEP) meeting:

*Name of SEP:* Lymphangioleiomyomatosis Registry (Telephone Conference Call).

*Date:* December 5, 1996.

*Time:* 2:00 p.m. est.

*Place:* 6701 Rockledge Drive, Room 7220, Bethesda, Maryland 20892.

*Contact Person:* C. James Scheirer, Ph.D., 6701 Rockledge Drive, Room 7220, Bethesda, Maryland 20892–7220, (301) 435–0266.

*Purpose/Agenda:* To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade

secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: October 31, 1996.

Paula N. Hayes,

*Acting Committee Management Officer, NIH.*

[FR Doc. 96–28629 Filed 11–6–96; 8:45 am]

**BILLING CODE 4140–01–M**

### **National Institute of Mental Health; Notice of Closed Meeting**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Institute of Mental Health Special Emphasis Panel:

*Agenda/Purpose:* To review and evaluate grant applications.

*Committee Name:* National Institute of Mental Health Special Emphasis Panel.

*Date:* November 12, 1996.

*Time:* 2 p.m.

*Place:* Parklawn Building, Room 9C–26, 5600 Fishers Lane, Rockville, MD 20857.

*Contact Person:* Sheri L. Schwartzback, Parklawn Building, Room 9C–26, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301–443–4843.

The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Program Numbers 93.242, 93.281, 93.282)

Dated: October 31, 1996.

Paula N. Hayes,

*Acting Committee Management Officer, NIH.*

[FR Doc. 96–28624 Filed 11–6–96; 8:45 am]

**BILLING CODE 4140–01–M**

### **National Institute on Drug Abuse; Notice of Closed Meetings**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute on Drug Abuse

(NIDA) Special Emphasis Panel meetings:

*Purpose/Agenda:* To evaluate and review grant applications.

*Name of Committee:* NIDA Special Emphasis Panel.

*Date:* November 14, 1996.

*Time:* 1:00 p.m.

*Place:* Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.

*Contact Person:* Rita Liu, Ph.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–22, Telephone (301) 443–2620.

*Name of Committee:* NIDA Special Emphasis Panel.

*Date:* November 19–20, 1996.

*Time:* 9:00 a.m.

*Place:* Double Tree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

*Contact Person:* Khurshed Asghar, Ph.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–22, Telephone (301) 443–2620.

*Name of Committee:* NIDA Special Emphasis Panel.

*Date:* November 20, 1996.

*Time:* 8:30 a.m.

*Place:* Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.

*Contact Person:* Mary C. Custer, Ph.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–22, Telephone (301) 443–2620.

This notice is being published less than 15 days prior to the meetings due to the urgent need to meet timing limitations imposed by the review and funding cycle.

The meetings will be closed in accordance with provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.277, Drug Abuse Scientist Development, Research Scientist Development, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs, National Institutes of Health)

Dated: October 31, 1996.

Paula N. Hayes,

*Acting Committee Management Officer, NIH.*

[FR Doc. 96–28625 Filed 11–6–96; 8:45 am]

**BILLING CODE 4140–01–M**

### **National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice